In the first marijuana industry buyout of 2021, Jazz Pharmaceuticals (NASDAQ: JAZZ) agreed to pay a hefty $7.6 billion to acquire GW Pharmaceuticals (NASDAQ: GWPH) , a developer of cannabis-based medications.
Will their fortunes suddenly change if the U.S. fully legalizes cannabis? Longtime Motley Fool contributor Eric Volkman and healthcare and cannabis bureau chief Corinne Cardina explore that possibility in this clip from Motley Fool Live recorded on Feb. 5, 2021 .
For further details see:
What Investors Need to Know About Jazz Pharmaceuticals' Planned Acquisition of GW Pharmaceuticals